keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/28419156/school-nurses-attitudes-towards-and-experiences-of-the-swedish-school-based-hpv-vaccination-programme-a-repeated-cross-sectional-study
#1
Maria Grandahl, Margareta Larsson, Tanja Tydén, Christina Stenhammar
The aim was to investigate school nurses' attitudes towards, and experiences of vaccination against human papillomavirus (HPV), and compare the results with a similar study three years earlier. School nurses (n = 736) from all counties in Sweden completed a questionnaire in spring 2016, four years after the implementation of the national HPV vaccination programme, and three years after the previous survey. Overall, the school nurses had more favourable attitudes towards the HPV vaccination programme compared to the study in 2013 (p = 0...
2017: PloS One
https://www.readbyqxmd.com/read/28404357/the-safety-and-immunogenicity-of-quadrivalent-hpv-qhpv-vaccine-in-systemic-lupus-erythematosus
#2
J Patricia Dhar, Lynnette Essenmacher, Renee Dhar, Ardella Magee, Joel Ager, Robert J Sokol
OBJECTIVE: This study evaluated the safety and immunogenicity of qHPV vaccine in SLE. METHODS: Subjects: 34 women ages 19-50years (yrs.) with mild to moderate SLE & minimally active or inactive SLE received qHPV vaccine at the standard dosing schedule. EXCLUSION CRITERIA: active SLE disease (SELENA-SLEDAI>2), history of severe SLE disease, deep venous thrombosis, on >400mg/day of hydroxychloroquine, on >15mg/day of prednisone, or active infections...
May 9, 2017: Vaccine
https://www.readbyqxmd.com/read/28359835/reasons-for-non-initiation-and-non-completion-of-hpv-vaccine-among-english-and-spanish-speaking-parents-of-adolescent-girls-a-qualitative-study
#3
Karen Albright, Juliana Barnard, Sean O'Leary, Steven Lockhart, Andrea Jimenez-Zambrano, Shannon Stokley, Amanda Dempsey, Allison Kempe
OBJECTIVE: The Advisory Committee on Immunization Practices recommends routine human papillomavirus (HPV) vaccination for females aged 11-12 years, yet vaccination rates remain low. We conducted a qualitative study to understand English- and Spanish-speaking parents' reasons for non-initiation or non-completion of the HPV vaccine series for their daughters. METHODS: Parents of females aged 12-15 years who had not initiated or not completed the HPV vaccine series were identified through administrative data in two large urban safety net health care systems in Colorado...
March 27, 2017: Academic Pediatrics
https://www.readbyqxmd.com/read/28355499/quadrivalent-hpv-vaccination-and-the-risk-of-adverse-pregnancy-outcomes
#4
Nikolai M Scheller, Björn Pasternak, Ditte Mølgaard-Nielsen, Henrik Svanström, Anders Hviid
Background The quadrivalent human papillomavirus (HPV) vaccine is recommended for all girls and women 9 to 26 years of age. Some women will have inadvertent exposure to vaccination during early pregnancy, but few data exist regarding the safety of the quadrivalent HPV vaccine in this context. Methods We assessed a cohort that included all the women in Denmark who had a pregnancy ending between October 1, 2006, and November 30, 2013. Using nationwide registers, we linked information on vaccination, adverse pregnancy outcomes, and potential confounders among women in the cohort...
March 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28346275/committee-opinion-no-704-human-papillomavirus-vaccination
#5
(no author information available yet)
Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and genital warts. Despite the benefits of HPV vaccines, only 41.9% of girls in the recommended age group, and only 28.1% of males in the recommended age group have received all recommended doses. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low...
March 24, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28337085/duty-to-advocate-human-papillomavirus-vaccination
#6
Kristen Nichols, Jennifer Girotto, Amy Mitchell-Van Steele, Sylvia Stoffella
Despite the excellent benefit-to-risk ratio for human papillomavirus (HPV) vaccination and recommendations for its routine use from the Advisory Committee on Immunization Practices (ACIP), significant controversy surrounding HPV vaccination continues to exist. In light of this controversy and continued low rates of vaccination among U.S. adolescents, the Pediatric Pharmacy Advocacy Group (PPAG) endorses the safety and efficacy of HPV vaccination and agrees with ACIP recommendations for protection of the U.S...
January 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/28328521/human-papillomavirus-first-and-second-generation-vaccines-current-status-and-future-directions
#7
Somayeh Pouyanfard, Martin Müller
It has been more than 10 years that the first prophylactic papillomavirus vaccine became available, although distribution has been mainly limited to the more affluent countries. The first two vaccines have been a great success, hundreds of millions of women and a much smaller number of men have been vaccinated ever since. In a few countries with high vaccination coverage, in particular Australia but also parts of Great Britain and others, clinical impact of vaccination programs is already visible and there are indications for herd immunity as well...
March 22, 2017: Biological Chemistry
https://www.readbyqxmd.com/read/28319456/reactogenicity-of-cervarix-and-gardasil-human-papillomavirus-hpv-vaccines-in-a-randomized-single-blind-trial-in-healthy-uk-adolescent-females
#8
Tao Haskins-Coulter, Jo Southern, Nick Andrews, Elizabeth Miller
One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in the national vaccination schedule at the time. Participants were blinded to treatment group until all 3 vaccinations had been given, while laboratory staff were masked during testing. For the majority of local and general reactions, recipients of both vaccines reported comparable frequencies...
March 20, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28266092/six-year-multi-centre-observational-post-marketing-surveillance-of-the-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-women-aged-10-25%C3%A2-years-in-korea
#9
Chul-Jung Kim, Rok Song, Jing Chen, Fernanda Taveres Da Silva, Kusuma B Gopala, Joon Hyung Kim, Dan Bi, Jong Sup Park
PURPOSE: To evaluate the safety of HPV-16/18 AS04-adjuvanted vaccine when administered as per the PI in Korea. METHODS: A total of 3084 women aged 10-25 years were enrolled in this post-marketing surveillance from 2008 to 2014. Subjects were invited to receive three doses of the vaccine (0, 1 and 6 months), and participants who received at least one dose were included in the analysis. Adverse events (AEs), adverse drug reactions (ADRs) and serious AEs (SAEs) were recorded after each dose...
March 7, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28193249/factors-associated-with-parental-reasons-for-no-intent-to-vaccinate-female-adolescents-with-human-papillomavirus-vaccine-national-immunization-survey-teen-2008-2012
#10
Vinay K Cheruvu, Madhav P Bhatta, Lauren N Drinkard
BACKGROUND: 1) To identify socio-demographic factors associated with parental "no-intent" for their 13-17 year old unvaccinated daughter to receive the human papillomavirus (HPV) vaccine series within the next twelve months, 2) to describe patterns in "no-intent" by socio-demographic factors, and 3) to identify socio-demographic factors associated with parental reasons for "no-intent". METHODS: Data from 2008-2012 National Immunization Survey - Teen (NIS - Teen) were examined in this study...
February 13, 2017: BMC Pediatrics
https://www.readbyqxmd.com/read/28190705/risk-of-autoimmune-diseases-and-human-papilloma-virus-hpv-vaccines-six-years-of-case-referent-surveillance
#11
Lamiae Grimaldi-Bensouda, Michel Rossignol, Isabelle Koné-Paut, Alain Krivitzky, Christine Lebrun-Frenay, Johanna Clet, David Brassat, Caroline Papeix, Marc Nicolino, Pierre-Yves Benhamou, Olivier Fain, Nathalie Costedoat-Chalumeau, Marie-France Courcoux, Jean-François Viallard, Bertrand Godeau, Thomas Papo, Patrick Vermersch, Isabelle Bourgault-Villada, Gerard Breart, Lucien Abenhaim
BACKGROUND: Safety of HPV vaccines is still in question due to reports of autoimmune diseases (ADs) following HPV immunization. OBJECTIVES: To assess the risk of ADs associated with HPV vaccination of female adolescents/young adults in France. METHODS: Systematic prospective case-referent study conducted to assess the risks associated with real-life use of HPV vaccines. Cases were female 11-25 years old with incident ADs [central demyelination/multiple sclerosis (CD/MS), connective tissue disease (CTD), Guillain-Barré syndrome (GBS), type-1 diabetes (T1D), autoimmune thyroiditis (AT), and idiopathic thrombocytopenic purpura (ITP)]...
February 9, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28153042/pragmatic-trial-of-an-intervention-to-increase-human-papillomavirus-vaccination-in-safety-net-clinics
#12
Maureen Sanderson, Juan R Canedo, Dineo Khabele, Mary K Fadden, Cynthia Harris, Katina Beard, Marilyn Burress, Helen Pinkerton, Cynthia Jackson, Tilicia Mayo-Gamble, Margaret K Hargreaves, Pamela C Hull
BACKGROUND: Human papillomavirus (HPV) infection has been causally linked to six cancers, and many disproportionately affect minorties. This study reports on the development and effectiveness of an intervention aimed at increasing HPV vaccine uptake among African American and Hispanic pediatric patients in safety-net clinics. METHODS: Formative research, community engagement, and theory guided development of the intervention. A clustered, non-randomized controlled pragmatic trial was conducted in four clinics providing healthcare for the underserved in Tennessee, U...
February 2, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28087890/overview-of-the-benefits-and-potential-issues-of-the-nonavalent-hpv-vaccine
#13
REVIEW
Luciano Mariani, Mario Preti, Paolo Cristoforoni, Carlo M Stigliano, Antonio Perino
HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined...
December 7, 2016: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/28073618/characteristics-of-adolescents-lacking-provider-recommended-human-papillomavirus-vaccination
#14
Melinda Krakow, Anna Beavis, Olivia Cosides, Anne F Rositch
PURPOSE: To characterize subgroups of teens in the United States for whom provider recommendation is less likely to impact human papillomavirus (HPV) vaccine initiation. METHODS: We analyzed provider-verified vaccination data from the Centers for Disease Control and Prevention's 2014 National Immunization Survey-Teen. Poisson regression models identified characteristics associated with the lack of HPV vaccine initiation among teens who received a provider recommendation (n = 12,742)...
May 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/28073220/what-do-we-know-about-the-safety-of-the-hpv-vaccines
#15
Peter C Gøtzsche
No abstract text is available yet for this article.
January 2017: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række
https://www.readbyqxmd.com/read/28053505/spotlight-on-the-9-valent-hpv-vaccine
#16
REVIEW
Pier Luigi Lopalco
Starting in 2006, vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries. Two vaccines have been successfully used, a bivalent vaccine targeting HPV-related cancers (bHPV) and a quadrivalent vaccine (qHPV) targeting both HPV-related cancers and genital warts. Between December 2014 and June 2015, a new nonavalent HPV vaccine (9vHPV) was granted marketing authorization in the USA and Europe. The 9vHPV was developed from the qHPV and includes five additional HPV types that should increase the level of protection toward HPV-related cancers...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28042137/immunogenicity-and-safety-of-human-papillomavirus-hpv-vaccination-in-asian-populations-from-six-countries-a-meta-analysis
#17
Didik Setiawan, Jos Luttjeboer, Koen B Pouwels, Jan C Wilschut, Maarten J Postma
Cervical cancer is a serious public-health problem in Asian countries. Since human papillomavirus (HPV) infection is the main risk factor for cervical cancer, HPV vaccination is considered a promising strategy to prevent cervical cancer. However, comprehensive immunogenicity and safety information for Asian populations is lacking. We searched four electronic databases including PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov. We reviewed selected manuscripts and extracted the pooled relative risk (RR) from immunogenicity and safety information on HPV vaccination among women in Asian countries...
March 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28003597/safety-and-immunogenicity-study-of-a-9-valent-human-papillomavirus-vaccine-administered-to-9-to-15-year-old-japanese-girls
#18
Satoshi Iwata, Shinya Murata, Shi Rong Han, Akira Wakana, Miyuki Sawata, Yoshiyuki Tanaka
A 9-valent human papillomavirus (HPV 6/11/16/18/31/33/45/52/58) virus-like particle (VLP) vaccine (9vHPV) has been proven highly efficacious in preventing anogenital disease related with vaccine HPV types in a pivotal Phase III study in women aged 16 to 26 years. We report here the results of an open-label phase III study conducted to bridge the findings in women age 16 to 26 years to Japanese girls aged 9 to 15 years. All subjects (n = 100) received a 3-dose regimen of 9vHPV vaccine at day 1, month 2 and month 6...
December 22, 2016: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27998015/efficacy-immunogenicity-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-chinese-women-aged-18-25%C3%A2-years-event-triggered-analysis-of-a-randomized-controlled-trial
#19
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, Yue-Mei Hu, Xun Zhang, Yi-Ju Zhang, Qin-Jing Pan, Wen-Hua Zhang, Fang-Hui Zhao, Cheng-Fu Zhang, Xiaoping Yang, Jia-Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan-Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi, Frank Struyf
We previously reported the results of a phase II/III, double-blind, randomized controlled study in Chinese women (NCT00779766) showing a 94.2% (95% confidence interval: 62.7-99.9) HPV-16/18 AS04-adjuvanted vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or higher (CIN1+) and/or 6-month (M) persistent infection (PI) with a mean follow-up of <2 years, and immunogenicity until 7 months post-dose 1. Here, we report efficacy and safety results from an event-triggered analysis with ~3 years longer follow-up, and immunogenicity until M24...
January 2017: Cancer Medicine
https://www.readbyqxmd.com/read/27940751/achieving-high-adolescent-hpv-vaccination-coverage
#20
Anna-Lisa M Farmar, Kathryn Love-Osborne, Katherine Chichester, Kristin Breslin, Kristi Bronkan, Simon J Hambidge
BACKGROUND AND OBJECTIVE: Despite national recommendations for adolescent human papillomavirus (HPV) vaccination, rates have lagged behind those of other adolescent vaccines. We implemented interventions and examined rates of vaccination coverage in a large, urban, safety net health care system to understand whether our tactics for achieving high rates of adolescent vaccination were successful. METHODS: Denver Health is an integrated urban safety net health system serving >17 000 adolescents annually...
November 2016: Pediatrics
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"